about
5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failureCardiovocal Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the LiteratureInhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migrationRiociguat: Mode of action and clinical development in pulmonary hypertensionThe molecular targets of approved treatments for pulmonary arterial hypertensionThe role of combination therapy in managing pulmonary arterial hypertensionCirculating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary HypertensionBasic features of hypoxic pulmonary vasoconstriction in miceStress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxiaTherapeutic efficacy of azaindole-1 in experimental pulmonary hypertensionNO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs.Safety and efficacy of exercise training in various forms of pulmonary hypertension.Fhl-1, a new key protein in pulmonary hypertension.Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury.SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertensionElectrophysiological studies in patients with pulmonary hypertension: a retrospective investigationThe safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension.Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension.The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary VasculatureHistological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease.Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension.Simvastatin as a treatment for pulmonary hypertension trial.Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodelingGlycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension.New trial designs and potential therapies for pulmonary artery hypertension.Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis.Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy.Cellular pathophysiology and therapy of pulmonary hypertension.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms.Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertensionHemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension.Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice
P50
Q21284504-85F1E310-19F7-4E3E-9F4D-E3A6D15D9F9EQ21296695-B1E8007F-064C-4E61-98EC-727C3CB576EDQ24812224-60ADDDC5-E1E5-4E42-88D3-58DD9BA24B3FQ26748684-A6A5010D-96C7-4073-809D-43DA738D3457Q26798308-367CCEA9-6AAA-4545-9400-19DDC3E23065Q26823839-09785780-BD62-4DA0-B2F2-146640ADFF63Q28109687-7B2374F1-8D49-4BBB-9A5B-82E0A77F3745Q28168498-7F512411-C3DC-4F3E-8896-67C56F39479EQ28239012-4C9C7EC9-C48E-4805-82CA-1D242F194320Q28284526-E07AB123-FD9C-4949-B879-5027D2E5C060Q32127934-F2396F51-17F8-4B24-B983-B3A62873384AQ33160952-F0366E95-3CEB-4A6D-9EE8-FDF2E894D036Q33363032-9502C77A-F7E3-4CF2-A683-1666243D083CQ33393513-9DC31CE9-2D54-45FF-AA6D-9977F44677FCQ33589653-0C7BC3CD-9E39-42F6-927E-740C46B8CB6CQ33612055-8EDC0E43-D9EA-4D75-B177-748BF6E6AF5EQ33738592-E11310D3-760F-43BA-9409-CBB7CDB02007Q33757692-8096282F-D805-4F8B-9F06-31C06D8313C1Q33788554-9B6B957A-BD64-44EC-A0C8-A9C644E37CB5Q33788576-8212015F-47AD-4B49-AE5B-99FA176DCA08Q33804336-D279976A-3396-420C-A721-D7583CF5A9F3Q33805932-6C19708D-2EF7-4D91-B8EA-AE8AFD286084Q33806163-F4AECF69-BF3A-4B92-8D75-C0A12BFA9E5EQ33868613-89532045-BA5A-469E-A547-EE15652FCE84Q33873485-9F405D4A-61BA-484C-A8F4-D08AF21A2012Q33886299-736D184E-E975-455F-8DE4-02F6321B5D2CQ33982467-72ECBF71-1718-4501-9099-CB304CF8C89AQ34035546-4D6C91AA-9DAF-4C1A-9718-0D585A825FA6Q34332085-AD246B04-9F07-4ACE-BD00-6ECE88AC64A8Q34402406-262BF8E0-2380-493F-8D72-3B9AFB2E27F4Q34468643-D12D8C44-3B89-41A7-826C-D736F6D686BFQ34491530-C2E69AC9-4E5A-4CEF-942B-B89E128568D5Q34666291-B5EBDD05-FD8B-482A-BB39-5F30A36D3F97Q34667642-6B5D3C4A-553B-4A6B-980E-DA46EE9071D1Q34786286-DF2FAEE6-CC7F-403E-AFF2-00E16E820B13Q34890985-01B398E2-E8F9-40ED-AA85-A36BAF54E596Q35128044-66935446-4641-4341-A2E4-6546D3F3CC75Q35185797-F94B6190-D600-456F-8B21-ECAFAEDBF408Q35517573-14B4D2C2-CB52-45A3-AB14-275F1845ADB2Q35658509-3ED3F11F-DB33-4420-A66F-78EF432E2854
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ardeschir Ghofrani
@ast
Ardeschir Ghofrani
@de
Ardeschir Ghofrani
@en
Ardeschir Ghofrani
@es
Ardeschir Ghofrani
@nl
Ardeschir Ghofrani
@sl
type
label
Ardeschir Ghofrani
@ast
Ardeschir Ghofrani
@de
Ardeschir Ghofrani
@en
Ardeschir Ghofrani
@es
Ardeschir Ghofrani
@nl
Ardeschir Ghofrani
@sl
prefLabel
Ardeschir Ghofrani
@ast
Ardeschir Ghofrani
@de
Ardeschir Ghofrani
@en
Ardeschir Ghofrani
@es
Ardeschir Ghofrani
@nl
Ardeschir Ghofrani
@sl
P214
P227
P101
P106
P214
P227
P31
P496
0000-0002-2029-4419
P569
1967-01-01T00:00:00Z
P7859
viaf-849555